Evidence map›Paper›PMID 32968084›Full record

ArticleScientific reports2020

Translation elongation factor 2 depletion by siRNA in mouse liver leads to mTOR-independent translational upregulation of ribosomal protein genes.

Maxim V Gerashchenko, Mikhail V Nesterchuk, Elena M Smekalova, Joao A Paulo, Piotr S Kowalski, Kseniya A Akulich, Roman Bogorad, Sergey E Dmitriev, Steven Gygi, Timofei Zatsepin and 3 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Maxim V Gerashchenko *Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA. mgerashchenko@bwh.harvard.edu.
Mikhail V Nesterchuk *Skolkovo Institute of Science and Technology, Skolkovo, Moscow Region, Russia.
Elena M Smekalova *David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02142, USA.
Joao A PauloDepartment of Cell Biology, Harvard Medical School, Boston, MA, 02115, USA.
Piotr S KowalskiDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02142, USA.
Kseniya A AkulichBelozersky Institute of Physico-Chemical Biology, Moscow State University, Moscow, 119992, Russia.
Roman BogoradDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02142, USA.
Sergey E DmitrievBelozersky Institute of Physico-Chemical Biology, Moscow State University, Moscow, 119992, Russia.
Steven GygiDepartment of Cell Biology, Harvard Medical School, Boston, MA, 02115, USA.
Timofei ZatsepinSkolkovo Institute of Science and Technology, Skolkovo, Moscow Region, Russia.
Daniel G AndersonDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02142, USA.
Vadim N GladyshevDivision of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
Victor E KotelianskySkolkovo Institute of Science and Technology, Skolkovo, Moscow Region, Russia. kotelianskiv@gmail.com.
Massachusetts Institute of Technology · USLomonosov Moscow State University · RUBrigham and Women's Hospital · USHarvard University · USSkolkovo Institute of Science and Technology · RU

Funding

Methionine sulfoxide reduction, selenium and agingR01AG021518 · NIA · UNIVERSITY OF NEBRASKA LINCOLN · PI GLADYSHEV, VADIM N. · 2003 to 2018
$5.0M
Systems level understanding of selenoprotein biosynthesisR01DK117149 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI GLADYSHEV, VADIM N. · 2018 to 2022
$2.4M
Advancing Multiplexed Isobaric Tag-based Strategies for Proteome ProfilingR01GM132129 · NIGMS · HARVARD MEDICAL SCHOOL · PI PAULO, JOAO A · 2019 to 2023
$1.7M
NIA NIH HHS R01 AG021518NIDDK NIH HHS R01 DK117149NIGMS NIH HHS R01 GM132129
6 · The paper itself

Abstract

Due to breakthroughs in RNAi and genome editing methods in the past decade, it is now easier than ever to study fine details of protein synthesis in animal models. However, most of our understanding of translation comes from unicellular organisms and cultured mammalian cells. In this study, we demonstrate the feasibility of perturbing protein synthesis in a mouse liver by targeting translation elongation factor 2 (eEF2) with RNAi. We were able to achieve over 90% knockdown efficacy and maintain it for 2 weeks effectively slowing down the rate of translation elongation. As the total protein yield declined, both proteomics and ribosome profiling assays showed robust translational upregulation of ribosomal proteins relative to other proteins. Although all these genes bear the TOP regulatory motif, the branch of the mTOR pathway responsible for translation regulation was not activated. Paradoxically, coordinated translational upregulation of ribosomal proteins only occurred in the liver but not in murine cell culture. Thus, the upregulation of ribosomal transcripts likely occurred via passive mTOR-independent mechanisms. Impaired elongation sequesters ribosomes on mRNA and creates a shortage of free ribosomes. This leads to preferential translation of transcripts with high initiation rates such as ribosomal proteins. Furthermore, severe eEF2 shortage reduces the negative impact of positively charged amino acids frequent in ribosomal proteins on ribosome progression.

Indexed as

AnimalsCell CycleElongation Factor 2 KinaseFemaleGene Knockdown TechniquesLiverMiceProtein BiosynthesisProteomeRibosomal ProteinsRNA, MessengerRNA, Small InterferingTOR Serine-Threonine KinasesUp-RegulationEef2k protein, mouseElongation Factor 2 KinasemTOR protein, mouseProteomeRibosomal ProteinsRNA, MessengerRNA, Small InterferingTOR Serine-Threonine Kinases

Identifiers

PMID32968084
PMCPMC7511953
OpenAlexW3089005554

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.